Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Involvement of the metabolic sensor GPR81 in cardiovascular control
Kristina Wallenius, Pia Thalén, Jan-Arne Björkman, Petra Johannesson, John Wiseman, Gerhard Böttcher, Ola Fjellström, Nicholas D. Oakes
Kristina Wallenius, Pia Thalén, Jan-Arne Björkman, Petra Johannesson, John Wiseman, Gerhard Böttcher, Ola Fjellström, Nicholas D. Oakes
View: Text | PDF
Research Article Cardiology Metabolism

Involvement of the metabolic sensor GPR81 in cardiovascular control

  • Text
  • PDF
Abstract

GPR81 is a receptor for the metabolic intermediate lactate with an established role in regulating adipocyte lipolysis. Potentially novel GPR81 agonists were identified that suppressed fasting plasma free fatty acid levels in rodents and in addition improved insulin sensitivity in mouse models of insulin resistance and diabetes. Unexpectedly, the agonists simultaneously induced hypertension in rodents, including wild-type, but not GPR81-deficient mice. Detailed cardiovascular studies in anesthetized dogs showed that the pressor effect was associated with heterogenous effects on vascular resistance among the measured tissues: increasing in the kidney while remaining unchanged in hindlimb and heart. Studies in rats revealed that the pressor effect could be blocked, and the renal resistance effect at least partially blocked, with pharmacological antagonism of endothelin receptors. In situ hybridization localized GPR81 to the microcirculation, notably afferent arterioles of the kidney. In conclusion, these results provide evidence for a potentially novel role of GPR81 agonism in blood pressure control and regulation of renal vascular resistance including modulation of a known vasoeffector mechanism, the endothelin system. In addition, support is provided for the concept of fatty acid lowering as a means of improving insulin sensitivity.

Authors

Kristina Wallenius, Pia Thalén, Jan-Arne Björkman, Petra Johannesson, John Wiseman, Gerhard Böttcher, Ola Fjellström, Nicholas D. Oakes

×

Figure 8

The GPR81 agonist, AZ2, exposure-dependently increases blood pressure in anesthetized, ventilated dogs.

Options: View larger image (or click on image) Download as PowerPoint
The GPR81 agonist, AZ2, exposure-dependently increases blood pressure in...
Immediately after a 15-minute baseline control period (0–15 minutes), AZ2 was administered i.v. in 5 consecutive escalating doses (5.5 to 550 nmol/kg/min, see Supplemental Figure 3A for diagram), commencing at 15 minutes and ending at 90 minutes, with the start of each dose change indicated by the broken red vertical lines. This was followed by a 30-minute washout period starting at the broken blue vertical line. Responses in AZ2-treated (red) or vehicle-treated (blue) dogs with data expressed as a percentage of their mean values during the baseline period. (A) Mean arterial pressure (MAP). P is treatment × time interaction significance (repeated-measures ANOVA). **P < 0.01, ***P < 0.001 AZ2 versus vehicle at the corresponding time period (Bonferroni corrected, n = 4). (B) Heart rate. (C) Cardiac output. (D) Total peripheral resistance (TPR). Results are the mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts